Snapshot from Jul 28, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ADMA Biologics securities class action
Regulatory securities lawsuit

ADMA Biologics securities class action

Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Jul 28, 2026

Sentiment
-30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The lawsuit may negatively impact ADMA's stock price due to investor concerns over alleged fraud and potential financial penalties. However, the impact is likely contained to ADMA and its shareholders, with limited broader market effects.

Biotechnology Pharmaceuticals
Event Summary

A securities class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) in the United States — United States District Court for the District of New Jersey. The lawsuit, brought by Kahn Swick & Foti, LLC on behalf of investors who purchased ADMA securities between August 9, 2024 and March 25, 2026, alleges that the company and certain executives made false and misleading statements in offering documents. Specifically, the complaint claims ADMA engaged in an undisclosed related party transaction, used channel stuffing to inflate revenue, and lacked adequate internal controls. When the truth was revealed, investors suffered damages. The lead plaintiff deadline is August 10, 2026.

Key Actions
90 ADMA Biologics issued misleading information
80 Kahn Swick & Foti notified investors of lawsuit ADMA Biologics
Entities Involved
stock
ADMA Biologics
ADMA Biologics is the defendant in the securities class action lawsuit, facing allegations of securities fraud. The company's reputation and stock price may suffer as a result.
Importance 100.0 Sentiment -40.0
priv
Kahn Swick & Foti
Kahn Swick & Foti is the law firm representing the plaintiff class in the lawsuit. The firm benefits from increased visibility and potential fees if the case succeeds.
Importance 60.0 Sentiment 10.0
per
Charles Foti
Charles Foti, former Louisiana Attorney General, is a partner at Kahn Swick & Foti and is named in the press release as a contact. His involvement lends credibility to the lawsuit.
Importance 20.0 Sentiment 5.0
per
Lewis Kahn
Lewis Kahn is the managing partner at Kahn Swick & Foti and is listed as a contact for investors. He is involved in the case management.
Importance 15.0 Sentiment 5.0
govactor
United States — United States District Court for the District of New Jersey
The court is where the lawsuit is pending. It will oversee the case and make rulings, but its role is procedural.
Importance 10.0 Sentiment 0.0
Relationships
ADMA Biologics related ↔ Kahn Swick & Foti
ADMA Biologics related ↔ United States — United States District Court for the District of New Jersey
Kahn Swick & Foti related ↔ Charles Foti
Kahn Swick & Foti related ↔ Lewis Kahn
Kahn Swick & Foti related ↔ United States — United States District Court for the District of New Jersey
Charles Foti law partner ↔ Lewis Kahn Charles Foti serves as a partner under Managing Partner Lewis Kahn at the securities litigation firm Kahn Swick & Foti.
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.